Summary
- Main use
- Improves liver MRI contrast enhancement (detection and characterization of lesions)
- Who receives it
- Adults · Children
- Adult administration
- Adults : Administer 0.1mL/kg of this drug as an intravenous bolus at a rate of approximately 2mL/sec. After administration of this drug, inject additional normal saline. Elderly patients aged 65 years or older : No dose adjustment is necessary. Patients with renal impairment : No dose adjustment is necessary. However, administer with caution to patients with severe renal impairment. Patients with hepatic impairment : No dose adjustment is necessary. Repeat administration : The safety and efficacy of repeated administration of this drug have not been established. Imaging After intravenous bolus administration of this drug, dynamic imaging during the arterial, portal venous, and equilibrium phases uses the different temporal enhancement patterns of various liver lesions as a basis for radiological lesion characterization. : The delayed (hepatocyte) phase is observed from 20 minutes after injection and lasts for at least 120 minutes. In patients requiring hemodialysis and patients with increased bilirubin levels (greater than 3mg/dL), the imaging duration is reduced to 60 minutes.
- Child administration
- Neonates, infants, children, and adolescents : The safety and efficacy of this drug have not been established in patients under 18 years of age.
Ingredients
- Importer
- Bayer korea
Efficacy & effects
Improves liver MRI contrast enhancement (detection and characterization of lesions)
View approved original textHide original text
Liver magnetic resonance imaging (MRI) contrast agent is used to clearly identify intrahepatic lesions and characterize the lesions. This assists in diagnosing and formulating treatment plans for various liver diseases such as liver cancer, liver cysts, and hepatitis. The contrast agent improves diagnostic accuracy by distinguishing liver tissue from lesions and providing accurate images. Due to these characteristics, it plays a critical role in precisely assessing the patient's liver condition and determining appropriate treatment measures.
How it is given
Adult administration
Adults : Administer 0.1mL/kg of this drug as an intravenous bolus at a rate of approximately 2mL/sec. After administration of this drug, inject additional normal saline. Elderly patients aged 65 years or older : No dose adjustment is necessary. Patients with renal impairment : No dose adjustment is necessary. However, administer with caution to patients with severe renal impairment. Patients with hepatic impairment : No dose adjustment is necessary. Repeat administration : The safety and efficacy of repeated administration of this drug have not been established. Imaging After intravenous bolus administration of this drug, dynamic imaging during the arterial, portal venous, and equilibrium phases uses the different temporal enhancement patterns of various liver lesions as a basis for radiological lesion characterization. : The delayed (hepatocyte) phase is observed from 20 minutes after injection and lasts for at least 120 minutes. In patients requiring hemodialysis and patients with increased bilirubin levels (greater than 3mg/dL), the imaging duration is reduced to 60 minutes.
Child administration
Neonates, infants, children, and adolescents : The safety and efficacy of this drug have not been established in patients under 18 years of age.
Precautions
Administration of this drug to patients with acute or chronic severe renal impairment may increase the risk of nephrogenic systemic fibrosis, a serious condition affecting the skin, muscles, and internal organs. Therefore, it should be used with extreme caution in patients with severely impaired kidney function, patients with hepatorenal syndrome, and patients before and after liver transplantation, and should be avoided if not necessary. This drug should never be administered via epidural injection due to the risk of serious side effects. Cases of gadolinium accumulation have been reported in brain scans of patients receiving multiple doses, necessitating careful judgment during repeated administration. This drug should not be used in patients with hypersensitivity to gadobutrol or those with artificial pacemakers, ferromagnetic implants, or persistent hypokalemia. Particular caution should be exercised when administering to patients with severe renal impairment or cardiovascular diseases, as well as to those with a history of allergies or asthma, as the risk of hypersensitivity reactions is heightened. After administration, side effects such as vomiting, headache, elevated blood pressure, and dizziness may occur, and rare but serious allergic reactions like anaphylaxis can occur. This drug may remain in the body for an extended time in patients with decreased kidney function, so renal function tests should be performed prior to administration, and this drug can be removed by hemodialysis. Use during pregnancy is only recommended if necessary, as its effects on the fetus are unclear, and breastfeeding should be suspended for 24 hours after administration. Since adverse reactions frequently occur within 30 minutes after the administration of this drug, patients should be monitored closely for at least 30 minutes post-administration. This drug should not be mixed with other medications, and discoloration or foreign materials must be checked before administration. In case of suspected overdose, there is a risk of cardiac arrhythmia, so immediate patient observation and enhanced cardiac monitoring should be conducted. Before administration, it is essential to carefully review the patient's medical history and clinical test results, and prepare medications and equipment needed for treating allergic reactions in case of emergencies. Finally, this drug should be opened immediately before use without dilution, as it is single-use, and any remaining solution must be disposed of.
Side effects
- NSF
- burning sensation
- itching
- red or dark spots
- skin swelling
- skin hardening
- skin stiffness
- yellow spots on the sclera
- joint stiffness
- movement disorders of arms and legs
Show 79 moreCollapse
- deep pain in the hip bone or ribs
- myasthenia
- vomiting
- headache
- increased blood pressure
- dizziness
- anaphylactic reaction
- hypersensitivity
- shock
- hypotension
- pharyngeal and laryngeal edema
- hives
- facial edema
- rhinitis
- conjunctivitis
- abdominal pain
- loss of sensation
- sneezing
- coughing
- pallor
- vertigo
- paresthesia
- taste disturbance
- olfactory disturbance
- akathisia
- tremor
- anxiety
- visual disturbance
- palpitations
- tachycardia
- flushing
- respiratory disorders
- shortness of breath
- nausea
- dry mouth
- oral discomfort
- increased salivation
- rash
- papular rash
- sweating
- back pain
- chest pain
- extravasation at the injection site
- burning at the injection site
- cold sensation at the injection site
- irritation at the injection site
- pain at the injection site
- chills
- fatigue
- abnormal sensation
- discomfort
- malaise
- increased liver aminotransferase
- decreased hemoglobin
- increased amylase
- white blood cell urinary excretion
- hyperglycemia
- increased albumin in urine
- hyponatremia
- increased inorganic phosphate
- decreased serum protein
- leukocytosis
- hypokalemia
- increased LDH
- prolonged QT syndrome
- increased serum iron
- increased bilirubin levels
- nausea
- hives
- paresthesia
- abdominal pain
- itching
- cold sweat
- maculopapular rash
- muscle stiffness
- fever
- hypotension
- pain at the biopsy site
- vasodilation
Not everyone experiences these, and they can vary from person to person.
Storage
This drug should be stored in a sealed container to avoid contact with air and is best kept at room temperature between 1 to 30 degrees Celsius. This is to maintain the drug's effectiveness and prevent degradation.
Appearance and packaging
Appearance
A clear liquid filling in a glass prefilled syringe or plastic prefilled syringe, which is colorless to light yellow or brownish or yellowish brown or yellow-green.
Package unit
Glass prefilled syringe: 10mL X 1 Plastic prefilled syringe: 10mL X 1
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.